Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 11;29(12):2299–2309. doi: 10.1158/1078-0432.CCR-22-3894

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2023 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 2. Additive benefit of cytotoxic chemotherapy to BRAF + EGFR–targeted therapy. Mice were randomized into one of four arms and dosed for 21 days: vehicle, FOLFIRI, E+C, or FOLFIRI + E+C. A, Percent change in tumor volume from day 0, ± SD of n = 8. B, Mean percent change in body weights from day 0, ± SD of n = 8. *, P < 0.05; **, P < 0.005. — Additive benefit of cytotoxic chemotherapy to BRAF + EGFR–targeted therapy. Mice were randomized into one of four arms and dosed for 21 days: vehicle, FOLFIRI, E+C, or FOLFIRI + E+C. A, Percent change in tumor volume from day 0, ± SD of n = 8. B, Mean percent change in body weights from day 0, ± SD of n = 8. *, P < 0.05; **, P < 0.005.